Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

NCT07010575 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Wilson's Disease

Interventions

DRUG: New TETA 4HCl Formulation
DRUG: Standard of Care

Sponsor

Orphalan